Alkem Laboratories Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

The said transaction is part of the company’s ongoing initiative of networking strategy and optimization of manufacturing facilities.

The sale includes all rights, title and interest in the leasehold land, factory building, assets and liabilities etc. associated with the said facility.

The business transfer agreement has been executed between the company and Rubicon Research on a slump sale basis. The company would receive a cash consideration of Rs 133.5 crore.

Rubicon Research is engaged in the business of development, manufacture, distribution and sale of pharmaceutical formulations. Rubicon does not belong to the promoter/ promoter group of Alkem Laboratories.

Alkem Laboratories is engaged in pharmaceutical business with global operations. The company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.

The company’s consolidated net profit jumped 11% to Rs 688.64 crore in Q2 FY25 as compared with Rs 620.52 crore in Q2 FY24. Net sales fell marginally 0.7% YoY to Rs 3414.67 crore in Q2 FY25.

Powered by Capital Market - Live News

Alkem Laboratories Ltd is up for a third straight session today. The stock is quoting at Rs 5567.2, up 1.54% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.04% on the day, quoting at 23803.900390625. The Sensex is at 78735.73, up 0.05%. Alkem Laboratories Ltd has slipped around 2.21% in last one month.

Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has slipped around 3.31% in last one month and is currently quoting at 23008.35, up 0.8% on the day. The volume in the stock stood at 1.05 lakh shares today, compared to the daily average of 1.21 lakh shares in last one month.

The benchmark January futures contract for the stock is quoting at Rs 5571.1, up 1.21% on the day. Alkem Laboratories Ltd is up 8.73% in last one year as compared to a 9.48% jump in NIFTY and a 37.57% jump in the Nifty Pharma index.

The PE of the stock is 30.31 based on TTM earnings ending September 24.

Powered by Capital Market - Live News

The company along with Enzene Bioscience entered into share subscription and shareholder agreement.

Sunsure Solarpark is a wholly owned subsidiary of Sunsure Energy is engaged in the business of generation, production and distribution of electricity from renewable energy sources.

The companies will acquire 26% stake in Sunsure Solarpark for total consideration of Rs 1.95 crore. The objective of this transaction is to purchase renewable power source in compliance with the environmental social governance thereby resulting in reduced power/ electricity costs.

In order to comply with regulatory requirement, the company and Enzene shall, being the captive users, collectively hold not less than 26% stake in the equity share capital of Sunsure Solarpark on a fully diluted basis and consume the solar energy generated therefrom, throughout the term of Share Subscription and Shareholder’s Agreement and certain other transaction documents.

Total contribution for the acquisition of equity share capital of Sunsure Solarpark will be Rs 1.95 crore, with Alkem Laboratories contributing Rs 93.60 lakh while Enzene Bioscience contributing Rs 1.01 crore. Alkem will hold 26% stake in Sunsure Solarpark while Enzene Bioscience will hold a 13.52% stake.

The said transaction will be completed by the end of April 2025.

Alkem Laboratories is engaged in pharmaceutical business with global operations. The company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.

The company’s consolidated net profit jumped 11% to Rs 688.64 crore in Q2 FY25 as compared with Rs 620.52 crore in Q2 FY24. Net sales fell marginally 0.7% YoY to Rs 3414.67 crore in Q2 FY25.

Powered by Capital Market - Live News

The Board of Directors of Alkem Laboratories at its meeting held today i.e.10 December 2024 approved the transfer of the trade generics business of the Company as a going concern, on a slump sale basis, to Alkem Wellness, a wholly owned subsidiary of the Company, incorporated in India.

The transaction is proposed to be effected through a business transfer agreement and will be effective on or before 1 April 2025 or such other date as may be mutually agreed between the parties, subject to customary closing conditions.

Powered by Capital Market - Live News